Novo Nordisk has licensed Genmab’s DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programmes.
Go deeper with GlobalData
The bispecific antibodies being developed will target a disease area outside of cancer therapeutics.
Genmab’s DuoBody platform is a proprietary technology platform for the discovery and development of bispecific antibodies, which binds to two different epitopes either on the same or on different targets.
DuoBody platform generated bispecific antibodies are expected to improve antibody therapy of cancer, autoimmune, and infectious and central nervous system disease.
Genmab CEO Jan van de Winkel said: “Our proprietary DuoBody technology can be used to create bispecific antibodies that target a wide variety of disease areas.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Today’s agreement with Novo Nordisk is an example of how we can leverage access to our unique state-of-the art antibody expertise and collaborations to generate diverse revenue streams in areas beyond cancer.”
As part of the deal, Novo Nordisk will pay an upfront payment of $2m to Genmab.
Novo Nordisk is also eligible to maintain exclusivity or take the licences forward on a non-exclusive basis, after an initial period of exclusivity for the two target combinations.
The deal will allow Genmab to receive potential development, regulatory and sales milestones of up to $250m for each exclusive licence of around $200m for each non-exclusive licence.
The company will also receive single-digit royalties on sales of any commercialised products.
